Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
70 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Sir Charles Gairdner Hospital
Nedlands, Perth, Australia
- Townsville Hospital
Douglas, Queensland, Australia
- Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
- Flinders Medical Centre
Bedford Park, South Australia, Australia
- Cancer Clinical Trials Centre (cctc)
Heidelberg, Victoria, Australia
- Tom Baker Cancer Center
Calgary, Alberta, Canada
- University of Alberta Princess Margaret Hospital
Edmonton, Alberta, Canada
- the Leukemia/bmt Program of Bc Vancouver General Hospital
Vancouver, British Columbia, Canada
- Cancercare Manitoba
Winnipeg, Manitoba, Canada
- Juravinski Cancer Centre
Hamilton, Ontario, Canada
- University Health Network (uhn) - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
- Centre Hospitalier Universitaire D'Angers
Angers, France
- Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
- Centre Hospitalier Universitaire Grenoble Alpes
La Tronche, France
- Unité D'Evaluation Thérapeutique En Onco-Hématologie (etho)
Marseille, France
- Saint-Louis Hospital
Paris, France
- Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Centre Hospitalier Universitaire de Poitiers
Poitiers, France
- Galway University Hospital
Galway, Ireland
- Irccs Casa Sollievo Della Sofferenza Hospital
San Giovanni Rotondo, FG, Italy
- Institute of Hematology and Medical Oncology "l. and A. Seràgnoli"
Bologna, Italy
- Istituto Scientifico Romagnolo Per Lo Studio E la Cura Dei Tumori (irst)
Meldola, Italy
- Hospital of Ravenna
Ravenna, Italy
- Fondazione Policlinico Tor Vergata, U.O.C. Ematologia
Roma, Italy
- Università Cattolica del Sacro Cuore (unicatt)
Rome, Italy
- Ca' Foncello Hospital
Treviso, Italy
- Vu University Medical Center
Amsterdam, Netherlands
- University Medical Center Groningen
Groningen, Netherlands
- University Medical Centre Utrecht
Utrecht, Netherlands
- Hospital San Pedro de Alcantra
Cáceres, Spain
- Hospital Mdacc
Madrid, Spain
- Hospital Universitario Fundación Jiménez Diaz
Madrid, Spain
- Hospital Virgen de la Victoria, Málaga
Málaga, Spain
- Clínica Universidad de Navarra
Pamplona, Spain
- Hospital Universitario de Salamanca
Salamanca, Spain
- University Hospital of Hospital Marqués de Valdecilla
Santander, Spain
- Hospital Universitari I Politècnic la Fe
Valencia, Spain
- Radcliffe Hospitals and University of Oxford
Oxford, England, United Kingdom
- Cardiff University School of Medicine
Cardiff, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Oct 2018
- Primary completion
- 31 Mar 2024
- Completion
- 31 Mar 2024
- Last update posted
- 29 Jul 2024
- Registered enrollment
- 388
- Registry id
- NCT03616470
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.